ClinicalTrials.gg
CompletedNCT07896122Updated Oct 26, 2026

Patient-Controlled Ambient Light to Reduce Pre-Visit Anxiety in Dermatology Patients

An interventional study of Patient-controlled ambient light (Serene Sphere) in Anxiety and Skin Neoplasms, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Stanford University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2026, registered Oct 2026).
Updated Oct 26, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Many patients feel anxious while waiting to see a dermatologist, especially in clinics that diagnose and treat skin cancer. The purpose of this study was to learn whether spending 10 minutes before the visit in an exam room lit by a tabletop colored-light device, which patients control themselves, lowers anxiety compared with usual room lighting. Adult patients at one Stanford dermatology clinic were assigned by clinic week: during intervention weeks the device was on and patients could choose its color and brightness with a handheld remote; during control weeks the room had standard lighting. Patients answered short questionnaires about how they felt when they arrived and again after 10 minutes in the room.

02

Conditions studied

  • Anxiety
  • Skin Neoplasms

Keywords

  • pre-visit anxiety
  • ambient lighting
  • colored light
  • patient control
  • dermatology
  • cutaneous oncology
  • clinic environment
03

In context

Anxiety Disorders

5,065 studies on the registry are indexed under Anxiety Disorders; 1,408 are open to participants now.

This study's enrollment of 120 is above the median of 80 across 4,339 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Stanford University is the lead sponsor of 2,162 studies on the registry; 429 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Scheduled for an outpatient appointment with the study dermatologist during the study period
  • Able to read English and provide informed consent

Exclusion criteria

Exclusion Criteria:

  • Known photosensitive epilepsy or seizure disorder triggered by colored lights
  • Significant visual impairment that would prevent perception of ambient light
  • Prior participation in this study
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Patient-controlled ambient light

    Participants spent 10 minutes alone in the examination room with the ambient light device switched on and could change its color and brightness with a handheld remote, after a brief demonstration by research staff.

    Other: Patient-controlled ambient light (Serene Sphere)

  • No intervention
    Standard lighting (control)

    Participants spent 10 minutes alone in the examination room under standard clinic lighting; the light device was not switched on and no remote was provided. The same anxiety questionnaires and vital signs were collected on arrival and after 10 minutes as in the intervention arm.

Interventions

  • OtherPatient-controlled ambient light (Serene Sphere)

    Tabletop ambient light with a frosted diffusing dome that fills the examination room with soft colored light at standard indoor brightness. A handheld remote lets the participant choose among preset color themes and adjust brightness. Research staff switched it on and briefly demonstrated the remote; the participant then spent 10 minutes alone in the room before any provider encounter. The device does not touch the participant or collect any data.

    Also known as: Serene Sphere

06

What researchers measure

Primary outcomes

  1. Change in State Anxiety (STAI-6) Score

    Six-item short form of the State-Trait Anxiety Inventory (STAI-6), prorated to a 20-80 scale; higher scores indicate more anxiety. Change = score after 10 minutes in the examination room minus score on arrival, compared between arms.

    Time frame: On arrival (before exposure) and 10 minutes later, before the provider encounter

Secondary outcomes

  1. Change in Anxiety Numeric Rating Scale (NRS) Score

    Single-item 0-10 numeric rating of anxiety about the appointment; higher scores indicate more anxiety. Change = score after 10 minutes in the examination room minus score on arrival, compared between arms.

    Time frame: On arrival (before exposure) and 10 minutes later, before the provider encounter

07

Study locations

1 site
  • Stanford Dermatology Clinic
    Redwood City, California 94063, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07896122
Responsible party
Lisa Zaba (Associate Professor of Dermatology, Stanford University) — Principal investigator
First posted
Oct 26, 2026
Start date
Jun 15, 2026
Primary completion
Aug 11, 2026
Completion
Aug 11, 2026
Last update
Oct 26, 2026

Study contacts

Lisa Zaba, MD, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion